Skip to main content

Moderna, Inc Value Stock - Dividend - Research Selection

Moderna

ISIN: US60770K1079 , WKN: A2N9D9

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness

2024-03-22
The fact that multiple Moderna, Inc. ( NASDAQ:MRNA ) insiders offloaded a considerable amount of shares over the past...

First Week of MRNA May 3rd Options Trading

2024-03-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cathie Wood sells $48 million of cloud tech stock

2024-03-22
Her Ark Innovation ETF has slipped 3.4% so far this year.

Biogen, Moderna, and 6 More Healthcare Stocks With Room to Grow

2024-03-21
After an abysmal 2023, healthcare stocks are nearly keeping pace with the broader market this year. The fund, which tracks healthcare stocks in the has returned 7.3% so far this year as of Tuesday’s market close—just a bit behind the broader index, which has returned 8.9%. Healthcare stocks fell deeply out of favor in 2023, amid a rush away from what had been thought of as defensive plays into hot tech stocks.

Is Cathie Wood Buying The Rumor? Ark More Than Doubles Stake In This COVID-19 Vaccine Maker Ahead Of Flurry Of Catalysts

2024-03-21
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery

2024-03-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Video: Nasdaq 100 Movers: MRNA, PDD

2024-03-20
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cathie Wood-Led Ark Invest Sheds Shares Of Jack Dorsey's Block And Coinbase As Bitcoin, Ethereum Take A Breather

2024-03-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Cathie Wood's Ark Invest Isn't Done Selling Shares Of Jack Dorsey-Led Block Yet — Sheds $7.5M Worth of Stock As Bitcoin Price Drops

2024-03-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024

2024-03-19
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.